Umoja Biopharma develops immunotherapies that reprogram patients’ T cells inside the body (in vivo) to attack cancer. Its main product approach is a CAR T-cell gene therapy platform designed to be produced in-house and sold as off-the-shelf regimens, enabling scalable treatment for both solid tumors and blood cancers that have not responded to other therapies. The treatment works by modifying the patient’s immune system directly in the body to create CAR T cells that can target and kill cancer cells, aiming for lasting remissions. Unlike many therapies that extract cells from a patient, modify them outside the body, and then reinsert them, Umoja Biopharma focuses on in-body cell reprogramming and in-house manufacturing to streamline delivery. The company differentiates itself through its in vivo, off-the-shelf CAR T approach and its goal of broad applicability across cancer stages, seeking to provide accessible, scalable cancer treatments across solid and hematologic cancers.
Company Size
201-500
Company Stage
Series C
Total Funding
$363M
Headquarters
Seattle, Washington
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?